found that the anti-tumor effect of anti-CTLA-4 or anti-PD-L1/anti-PD-1 was significantly increased in IDO-deficient melanoma-bearing mice (113), suggesting that the combination of IDO inhibitors with ICIs may enhance the anti-tumor ability in clinical therapy. Here, CTLA4 is linked to melanoma.